Professor of Urology and Oncology
Johns Hopkins Medical Institutions
Director, Urologic Oncology
Johns Hopkins Bayview Medical Center
Director, Urologic Oncology Fellowship
Dr. Pavlovich came to Johns Hopkins after completing a Urologic Oncology fellowship at the National Cancer Institute. His practice is dedicated primarily to the treatment of prostate, kidney and bladder cancer, as well as to the treatment of benign prostatic diseases. He is experienced in open, laparoscopic, and robotic minimally invasive surgery for the management of urologic tumors, including nerve-sparing laparoscopic and robot- assisted radical prostatectomy, laparoscopic and robotic nephrectomy and partial nephrectomy, and robotic radical cystectomy.
A particular expertise of his is the robotic extraperitoneal (or retroperitoneal) approach to the prostate and kidney for patients with prostate or kidney cancer. This approach, which avoids entry into the abdominal cavity, is ideally suited for patients that have had prior abdominal or inguinal operations (e.g. hernia repairs, appendectomy, colectomy) or who have inflammatory conditions (e.g. Crohn’s disease, ulcerative colitis, diverticulitis) that might make an abdominal robotic approach more hazardous.
Dr. Pavlovich’s research has been funded by the National Institutes of Health, Department of Defense, industry, and through institutional grants. He continues to work on early detection and risk stratification of prostate and kidney cancer using novel noninvasive urinary, blood, and imaging tests. As Director of Urologic Oncology at Johns Hopkins Bayview Medical Center, he continues to treat cancer with an emphasis on minimizing morbidity and maximizing quality of life, while exposing his patients to the latest treatment options and techniques. In addition, as Fellowship Director of Urologic Oncology for the Brady Urological Institute, he oversees the selection and training of the next generation of leaders in the field.
Dr. Pavlovich is accepting new patients and is delighted to offer second opinions regarding the treatment of any urologic malignancy.